Kailera opens the global KaiNETIC Phase 3 program for ribupatide

Kailera Therapeutics has opened enrollment for its first global Phase 3 study of ribupatide, an experimental weight-loss injection also known by the code name KAI-9531. The trial is registered on ClinicalTrials.gov as NCT07284875 and is studying people living with obesity or overweight who also have weight-related health problems but do not have diabetes ^[1].

A second registered trial, NCT07284979, is designed to compare once-weekly ribupatide directly against semaglutide and against placebo in adults with obesity who do not have diabetes ^[2]. Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus. A head-to-head design like this lets researchers see how ribupatide's weight-loss results compare with an approved drug already used by millions of patients, rather than only comparing it against a placebo.

The sources reviewed for this story do not include the specific number of participants planned for either trial, the exact enrollment start date, the doses being tested, or the expected completion date. Those details are not yet known from the available ClinicalTrials.gov listings ^[1][2]. Broader background on ribupatide describes it as licensed from Jiangsu Hengrui's HRS9531 compound and says it is considered the most advanced of several licensing deals that have brought Chinese-developed obesity drugs to Western drug companies, but the two trial registry pages alone do not detail the company's origin story or licensing terms.

Why it matters for patients

For people currently using or considering semaglutide-based drugs, a direct comparison trial matters because it could eventually show whether a new drug produces more, less, or similar weight loss compared with a medicine already on pharmacy shelves. Right now, though, ribupatide is not approved for use in the United States. It is only being studied in clinical trials, and the population in these two studies is limited to adults with obesity or overweight and weight-related conditions who do not have diabetes ^[1][2]. People with diabetes, and anyone outside the age or health criteria set by the trial protocols, would not be eligible to enroll based on what is described in these listings.

Because enrollment has only just begun on the first trial, there is no safety or effectiveness data yet to review. Patients should not expect near-term changes to what is available at the pharmacy because of this development. Clinical trials of this kind, especially ones testing a drug against an active comparator like semaglutide, commonly take one to several years to complete, though the sources here do not give a specific timeline for either study ^[1][2].

For patients who follow the broader GLP-1 drug market, this development is one sign that companies outside the current group of approved obesity-drug makers are working on new options. Whether ribupatide ultimately reaches U.S. pharmacies, and how it might compare in cost, dosing, or side effects to Ozempic, Wegovy, Mounjaro, Zepbound, or Foundayo, is not addressed in the sources reviewed and remains unknown at this stage.

What happens next

The ClinicalTrials.gov listings confirm that NCT07284875 and NCT07284979 are open studies, with NCT07284979 specifically built to compare ribupatide against semaglutide and placebo ^[1][2]. Beyond this enrollment stage, the sources reviewed do not specify interim data readouts, a third trial's registry details, or a projected filing date with U.S. regulators. Readers who want to track specific milestones, such as enrollment completion or first results, can follow the individual trial registrations directly, since those are the only documents available and consulted for this story ^[1][2].